

ABSTRACT

To provide novel eyedrops for suppressing myopia progression capable of readily suppressing the progression of myopia by simply being administered.

The above-described problem is solved by eyedrops for suppressing myopia progression containing an α 1-blocker. The α 1-blocker is preferably contained as an α 1-blocker salt within a range greater than 0.001 mg/mL and up to 1.4 mg/mL. The α 1-blocker includes one or two or more ingredients selected from bunazosin, prazosin, urapidil, moxislyte, and corynanthine.

Selected drawing: Fig. 2